ng28ÄϹ¬ºÍ²³½¡ÓÚ2024Äê12ÔÂ5ÈÕÁªºÏÐû²¼£¬ÈËÔ´»¯¿ÉÈÜÐÔ¾Û¼¯ÐԦµí·ÛÑùÂÑ°×£¨A¦Â£©µ¥¿Ë¡¿¹ÌåÂØ¿¨Ä¹»ñµÃÄ«Î÷¸çÁª°îÎÀÉúΣº¦±£»¤Î¯Ô±»á£¨COFEPRIS£©Åú×¼£¬ÓÃÓÚÔçÆÚ°¢¶û´Äº£Ä¬²¡*£¨AD£©µÄÖÎÁÆ¡£

 

ÂØ¿¨Ä¹¿ÉÑ¡ÔñÐÔ½áºÏ¿ÉÈÜÐÔA¦Â¾Û¼¯Ì壨ԭÏËά**£©£¬ÒÔ¼°ADÖÐA¦Â°ß¿éµÄÖ÷ÒªÉí·Ö¡ª¡ª²»ÈÜÐÔA¦Â¾Û¼¯Ì壨ÏËά£©£¬´Ó¶ø¼õÉÙ´óÄÔÖеÄA¦ÂÔ­ÏËάºÍA¦Â°ß¿é¡£ÂØ¿¨Ä¹ÊÇÊ׸ö»ñÅúµÄͨ¹ý´Ë»úÖƼõ»º¼²²¡½øÕ¹ËٶȺÍÈÏÖª¼°¹¦Ð§Ë¥Í˵ÄÖÎÁÆÒ©Îï¡£Æù½ñΪֹ£¬ÂØ¿¨Ä¹ÒÑÔÚÃÀ¹ú¡¢ÈÕ±¾¡¢Öйú¡¢º«¹ú¡¢ÖйúÏã¸Û¡¢ÒÔÉ«ÁС¢°¢À­²®ÁªºÏÇõ³¤¹úºÍÓ¢¹ú£¨±±°®¶ûÀ¼³ýÍ⣩»ñµÃÅú×¼ÉÏÊÐ¡£

 

´Ë´ÎÅú×¼ÊÇ»ùÓÚng28ÄϹ¬È«Çò´óÐÍIIIÆÚÁÙ´²ÊÔÑéClarity ADÑо¿µÄÊý¾Ý¡£ÔÚÕâÏîÑо¿ÖУ¬ÂØ¿¨Ä¹µÖ´ïÁËÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖյ㣬ÇÒ½á¹û¾ßÓÐÏÔÖøͳ¼ÆѧÒâÒå¡£^1,2

 

¾Ý²âË㣬ÔÚÄ«Î÷¸ç£¬Óнü 130 ÍòÈË»¼ÓÐAD³£¬AD±»ÈÏΪÊdzմôÖ¢×î³£¼ûµÄ²¡Òò£¬Í¨³£Õ¼²¡ÀýµÄ60-70%¡£

 

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖУ¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

*ÓÉ°¢¶û´Äº£Ä¬²¡ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍ°¢¶û´Äº£Ä¬²¡Çá¶È³Õ´ôµÄͳ³Æ¡£

**Ô­ÏËά±»ÈÏÊǵ¼ÖÂAD»¼ÕßµÄÄÔËðÉ˵ÄÔªÐ×£¬ÆäËùº¬¶¾ÐÔÊÇA¦ÂÖÐ×î´óµÄ£¬ÔÚÓëÕâÖÖ½øÐÐÐÔË¥ÈõµÄ¼²²¡Ïà¹ØµÄÈÏ֪˥ÍËÖÐÆðÖ÷Òª×÷ÓÃ⁴¡£Ô­ÏËά¶Ô´óÄÔÉñ¾­ÔªÔì³ÉËðÉË£¬½ø¶øͨ¹ý¶àÖÖ»úÖƶÔÈÏÖª¹¦Ð§±¬·¢¸ºÃæÓ°Ï죬²»µ«Ôö¼ÓÁ˲»ÈÜÐԦ°߿éµÄÐγÉ£¬²¢ÇÒÔö¼ÓÁ˶ÔÄÔϸ°ûĤºÍÉñ¾­Ï¸°ûÖ®¼ä»òÉñ¾­Ï¸°ûÓëÆäËûϸ°ûÖ®¼äͨ±¨ÐźŵÄÁ¬½ÓµÄÖ±½ÓËðÉË¡£¼õÉÙÔ­ÏËά¿É¼õÉÙ¶Ô´óÄÔÉñ¾­ÔªµÄËðÉ˺ÍÈÏÖª¹¦Ð§ÕÏ°­À´×èÖ¹°¢¶û´Äº£Ä¬²¡µÄ½øÕ¹⁵¡£

 

ýÌåÁªÏµÈË

ng28ÄϹ¬Öêʽ»áÉ繫¹Ø²¿ µç»°£º03-3817-5120

²³½¡¹«Ë¾¹«¹²ÊÂÎñ²¿ ?ÓÊÏä:public.affairs@biogen.com

 

 

²Î¿¼ÎÄÏ×

1. Eisai presents full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer’s disease

at Clinical Trials on Alzheimer’s Disease (CTAD) conference. Available at:

https://www.eisai.co.jp/news/2022/news202285.html

2. van Dyck. C, et al. Lecanemab in Early Alzheimer¡¯s Disease. The New England Journal of Medicine. DOI:

10.1056/NEJMoa2212948. https://www.nejm.org/doi/full/10.1056/NEJMoa2212948

3. Secretar¨ªa de Salud. Enfermedad de Alzheimer, demencia m¨¢s com¨²n que afecta a personas adultas mayores.

Oct 2021. https://www.gob.mx/salud/es/articulos/enfermedad-de-alzheimer-demencia-mas-comun-queafecta-

a-personas-adultas-mayores?idiom=e

4. Amin L, Harris DA. A¦Â receptors specifically recognize molecular features displayed by fibril ends and

neurotoxic oligomers. Nat Commun. 2021;12:3451. doi:10.1038/s41467-021-23507-z

5. Ono K, Tsuji M. Protofibrils of Amyloid-¦Â are Important Targets of a Disease-Modifying Approach for

Alzheimer’s Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID:PMC7037706.